Zydus Lifes gains after receiving approval from COFEPRIS for Bevacizumab biosimilar

Zydus Lifesciences rose 1.52% to Rs 1161.95 after the Mexican regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk) granted marketing approval to the company for Bhava, a Bevacizumab biosimilar.